|
Market Closed -
Nasdaq
16:00:00 2026-09-15 EDT
|
5-day change | 1st Jan Change | ||
| 3.130 USD | -10.57% |
|
-22.33% | +131.85% |
Company Valuation: Zentalis Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 3,808 | 1,149 | 1,072 | 215.9 | 87.41 | 296.3 | - | - |
| Change | - | -69.82% | -6.72% | -79.86% | -59.52% | 238.99% | - | - |
| Enterprise Value (EV) 1 | 3,468 | 712 | 589.2 | -155.1 | -158.5 | 91.77 | 156.9 | 143.6 |
| Change | - | -79.47% | -17.25% | -126.33% | -2.15% | 157.91% | 70.92% | -8.45% |
| P/E | -22.6x | -4.5x | -3.39x | -1.3x | -0.71x | -1.43x | -1.61x | -1.94x |
| PBR | 10.5x | 2.75x | 2.45x | 0.64x | 0.43x | 1.62x | 3.48x | 3.6x |
| PEG | - | -0.2x | 15.19x | 0x | 0x | -0.1x | 0.1x | 0.1x |
| Capitalization / Revenue | - | - | - | 3.2x | - | - | 18.1x | 4.28x |
| EV / Revenue | - | - | - | -2.3x | - | - | 9.58x | 2.07x |
| EV / EBITDA | -16.1x | -3.15x | -1.98x | 0.82x | 1.04x | -0.51x | -0.75x | -1.04x |
| EV / EBIT | -16x | -3.13x | -1.97x | 0.6x | 1.04x | -0.53x | -0.89x | -0.84x |
| EV / FCF | -16.9x | -3.3x | -2.83x | 0.91x | 1.27x | -0.57x | -0.91x | -0.96x |
| FCF Yield | -5.92% | -30.3% | -35.4% | 110% | 79% | -174% | -110% | -104% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -3.72 | -4.48 | -4.47 | -2.33 | -1.91 | -2.183 | -1.943 | -1.617 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | 67.42 | - | - | 16.38 | 69.26 |
| EBITDA 1 | -216 | -225.9 | -298.1 | -189.9 | -152.1 | -178.5 | -208.3 | -138.4 |
| EBIT 1 | -216.5 | -227.3 | -299.5 | -258.6 | -152.8 | -172.8 | -177 | -170.3 |
| Net income 1 | -158.7 | -236.8 | -292.2 | -165.8 | -137.1 | -164.6 | -168.9 | -162.2 |
| Net Debt 1 | -339.9 | -437.4 | -482.9 | -371.1 | -245.9 | -204.5 | -139.5 | -152.7 |
| Reference price 2 | 84.060 | 20.140 | 15.150 | 3.030 | 1.350 | 3.130 | 3.130 | 3.130 |
| Nbr of stocks (in thousands) | 45,306 | 57,069 | 70,766 | 71,265 | 64,751 | 94,672 | - | - |
| Announcement Date | 2/24/22 | 3/1/23 | 2/27/24 | 3/26/25 | 3/26/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.6x | - | -0.71x | - | 331M | |
| 20.63x | 7.28x | 14.62x | 1.44% | 70.24B | |
| 32.28x | 9.34x | 45.05x | 0.04% | 62.63B | |
| -76.7x | 14.8x | -71.37x | -.--% | 27.36B | |
| 29.77x | 6.32x | 16.41x | -.--% | 25.71B | |
| -15.03x | 5.62x | -7.06x | -.--% | 24.83B | |
| 26.45x | 5.03x | 16.73x | -.--% | 19.52B | |
| 44.88x | 16.47x | 33.42x | 0.34% | 15.51B | |
| -15.8x | 3569.89x | -18.25x | -.--% | 14.69B | |
| 1267.62x | 36.68x | 797.93x | -.--% | 14.66B | |
| Average | 131.25x | 407.94x | 82.68x | 0.2% | 27.55B | |
| Weighted average by Cap. | 77.43x | 200.44x | 52.34x | 0.4% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ZNTL Stock
- Valuation Zentalis Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
